

---

**Specimen Collected: 16-Jun-23 15:34**

NMO/AQP4-IgG CBA, CSF Rflx Procedure	Received: 16-Jun-23 15:34 Result	Report/Verified: 16-Jun-23 15:35 Units	Reference Interval
NMO/AQP4 Ab IgG CBA-IFA Screen, CSF	<b>Detected</b> * t1 i1		[ < 1:1 ]

NMO/AQP4-Ab IgG Titer by CBA-IFA, CSF Procedure	Received: 16-Jun-23 15:34 Result	Report/Verified: 16-Jun-23 15:35 Units	Reference Interval
NMO/AQP4 Ab IgG CBA-IFA Titer, CSF	<b>1:40</b> * i2		[ < 1:1 ]

**Interpretive Text**

t1: 16-Jun-23 15:34 (NMO/AQP4 Ab IgG CBA-IFA Screen, CSF)  
Aquaporin-4 Receptor Antibody, IgG is detected. Titer results to follow.

**Test Information**

i1: NMO/AQP4 Ab IgG CBA-IFA Screen, CSF  
INTERPRETIVE INFORMATION: NMO/AQP4 Ab IgG CBA-IFA Screen,  
CSF

Neuromyelitis optic (NMO) commonly presents with optic neuritis or longitudinally extensive transverse myelitis. Approximately 75 percent of patients with NMO have antibodies to the aquaporin-4 (AQP4) receptor. While the absence of AQP4 receptor antibodies does not rule out a diagnosis of NMO, presence of this antibody is diagnostic for NMO.

This indirect fluorescent antibody assay utilizes AQP4 receptor transfected cell lines for the detection and semiquantification of AQP4 IgG antibody.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

i2: NMO/AQP4 Ab IgG CBA-IFA Titer, CSF  
INTERPRETIVE INFORMATION: NMO/AQP4 Ab IgG CBA-IFA Titer, CSF

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

---

\*=Abnormal, #=Corrected, C=Critical, f=Result Footnote, H-High, i-Test Information, L-Low, t-Interpretive Text, @=Performing lab

---

**Unless otherwise indicated, testing performed at:**

**ARUP Laboratories**

500 Chipeta Way, Salt Lake City, UT 84108

Laboratory Director: Jonathan R. Genzen, MD, PhD

**ARUP Accession:** 23-167-900145

**Report Request ID:** 17763713

**Printed:** 19-Jun-23 11:31

Page 1 of 1